Alexander Zehnder, CureVac CEO (Bernd Wei'brod/picture-alliance/dpa/AP Images)

GSK re­works Cure­Vac deal, pay­ing $429M up­front to grab con­trol of mR­NA flu and Covid vac­cines 

GSK is hand­ing mR­NA vac­cine part­ner Cure­Vac €400 mil­lion ($429 mil­lion) up­front to take over full rights to the in­fluen­za and Covid vac­cine can­di­dates they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.